# BRISTOL MYERS SQUIBB CO (BMY)

Informational only - not investment advice.

CIK: 0000014272
SIC: 2834 Pharmaceutical Preparations
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/)
Latest 10-K filed: 2026-02-11
SEC page: https://www.sec.gov/edgar/browse/?CIK=14272
Filing source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-11 · accession 0000014272-26-000004 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000014272.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 48,194,000,000 USD | 2025 | verified |
| Net income | 7,054,000,000 USD | 2025 | verified |
| Assets | 90,038,000,000 USD | 2025 | verified |
| Free cash flow | 12,845,000,000 USD | 2025 | computed |
| Net margin | 14.64% | 2025 | computed |
| Revenue YoY | -0.22% | 2025 | computed |
| ROE | 38.19% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

Peer groups: [Large-cap biopharma](/compare/pharma/) · SIC 2834 Pharmaceutical Preparations

No market price, no rating, no forecast on this site. Not investment advice.

## Peer comparisons including BMY

- Large-cap biopharma: [peer review](/compare/pharma/) · [market-risk page](/compare/pharma/risk/)

### Peer percentile fingerprint

| Ratio | BMY | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 14.6% | 1.0% | 71 | 107 |
| Revenue growth | -0.2% | 14.7% | 27 | 127 |
| FCF margin | 26.7% | -14.0% | 85 | 127 |
| ROE | 38.2% | -30.7% | 94 | 171 |
| ROA | 7.8% | -21.8% | 84 | 187 |
| Liabilities / equity | 3.87 | 0.38 | 88 | 173 |
| Current ratio | 1.26 | 4.89 | 4 | 188 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 48194000000 | USD | 2025 | 2026-02-11 |
| Net income | 7054000000 | USD | 2025 | 2026-02-11 |
| Assets | 90038000000 | USD | 2025 | 2026-02-11 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-11. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000014272.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 19,427,000,000 | 20,776,000,000 | 22,561,000,000 | 26,145,000,000 | 42,518,000,000 | 46,385,000,000 | 46,159,000,000 | 45,006,000,000 | 48,300,000,000 | 48,194,000,000 |
| Net income | 4,457,000,000 | 1,007,000,000 | 4,920,000,000 | 3,439,000,000 | -9,015,000,000 | 6,994,000,000 | 6,327,000,000 | 8,025,000,000 | -8,948,000,000 | 7,054,000,000 |
| Diluted EPS | 2.65 | 0.61 | 3.01 | 2.01 | -3.99 | 3.12 | 2.95 | 3.86 | -4.41 | 3.46 |
| Operating cash flow | 3,058,000,000 | 5,275,000,000 | 7,066,000,000 | 8,210,000,000 | 14,052,000,000 | 16,207,000,000 | 13,066,000,000 | 13,860,000,000 | 15,190,000,000 | 14,156,000,000 |
| Capital expenditures | 1,215,000,000 | 1,055,000,000 | 951,000,000 | 836,000,000 | 753,000,000 | 973,000,000 | 1,118,000,000 | 1,209,000,000 | 1,248,000,000 | 1,311,000,000 |
| Dividends paid | 2,547,000,000 | 2,577,000,000 | 2,613,000,000 | 2,679,000,000 | 4,075,000,000 | 4,396,000,000 | 4,634,000,000 | 4,744,000,000 | 4,863,000,000 | 5,045,000,000 |
| Share buybacks | 231,000,000 | 2,469,000,000 | 320,000,000 | 7,300,000,000 | 1,546,000,000 | 6,287,000,000 | 8,001,000,000 | 5,155,000,000 | 0.00 | 0.00 |
| Assets | 33,707,000,000 | 33,551,000,000 | 34,986,000,000 | 129,944,000,000 | 118,481,000,000 | 109,314,000,000 | 96,820,000,000 | 95,159,000,000 | 92,603,000,000 | 90,038,000,000 |
| Liabilities | 17,360,000,000 | 21,704,000,000 | 20,859,000,000 | 78,246,000,000 | 80,599,000,000 | 73,308,000,000 | 65,702,000,000 | 65,674,000,000 | 76,215,000,000 | 71,533,000,000 |
| Stockholders' equity | 16,177,000,000 | 11,741,000,000 | 14,031,000,000 | 51,598,000,000 | 37,822,000,000 | 35,946,000,000 | 31,061,000,000 | 29,430,000,000 | 16,335,000,000 | 18,473,000,000 |
| Cash and cash equivalents | 4,237,000,000 | 5,421,000,000 | 6,911,000,000 | 12,346,000,000 | 14,546,000,000 | 13,979,000,000 | 9,123,000,000 | 11,464,000,000 | 10,346,000,000 | 10,209,000,000 |
| Free cash flow | 1,843,000,000 | 4,220,000,000 | 6,115,000,000 | 7,374,000,000 | 13,299,000,000 | 15,234,000,000 | 11,948,000,000 | 12,651,000,000 | 13,942,000,000 | 12,845,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 22.94% | 4.85% | 21.81% | 13.15% | -21.20% | 15.08% | 13.71% | 17.83% | -18.53% | 14.64% |
| Return on equity | 27.55% | 8.58% | 35.07% | 6.66% | -23.84% | 19.46% | 20.37% | 27.27% | -54.78% | 38.19% |
| Return on assets | 13.22% | 3.00% | 14.06% | 2.65% | -7.61% | 6.40% | 6.53% | 8.43% | -9.66% | 7.83% |
| Liabilities / equity | 1.07 | 1.85 | 1.49 | 1.52 | 2.13 | 2.04 | 2.12 | 2.23 | 4.67 | 3.87 |
| Current ratio | 1.55 | 1.55 | 1.66 | 1.60 | 1.58 | 1.52 | 1.25 | 1.43 | 1.25 | 1.26 |

## As-reported value updates

3 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/BMY/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-30. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000014272.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 0.75 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 1.07 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.99 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 10,966,000,000 | 1,928,000,000 | 0.93 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 11,477,000,000 | 1,762,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 11,865,000,000 | -11,911,000,000 | -5.89 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 12,201,000,000 | 1,680,000,000 | 0.83 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 11,892,000,000 | 1,211,000,000 | 0.60 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 12,342,000,000 | 72,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 11,201,000,000 | 2,456,000,000 | 1.20 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 12,269,000,000 | 1,310,000,000 | 0.64 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 12,222,000,000 | 2,201,000,000 | 1.08 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 12,502,000,000 | 1,087,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 11,489,000,000 | 2,677,000,000 | 1.31 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 12,973,000,000 | 3,317,000,000 | 1.62 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from BMY's latest 10-K: [/company/BMY/business/](/company/BMY/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from BMY's latest 10-K: [/company/BMY/risk-factors/](/company/BMY/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-07-30
Report date: 2026-06-30

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related footnotes included elsewhere in this Quarterly Report on Form 10-Q to enhance the understanding of our results of operations, financial condition and cash flows. Certain amounts in this Quarterly Report on Form 10-Q may not sum due to rounding. Percentages have been calculated using unrounded amounts.

EXECUTIVE SUMMARY

Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns. Our R&D strategy is designed to invest in the most promising science and to consistently execute in a way that translates that science into new medicines with the highest probability of success. To execute this strategy, we focus on three key priorities: science, execution, and value. Additionally, we are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future. For further information on our strategy, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Executive Summary—Strategy" in our 2025 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.

In 2026, we made meaningful progress advancing our pipeline, highlighted by: (i) FDA acceptance of our NDA for iberdomide in RRMM with a PDUFA date of August 17, 2026; (ii) FDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027; (iii) positive interim Phase II results from the ROSETTA Lung-02 study of pumitamig in patients with previously untreated advanced NSCLC; (iv) positive interim results from two Phase III studies conducted in China for iza-bren in heavily pretreated, unresectable locally advanced or metastatic TNBC and recurrent or metastatic ESCC; and (v) FDA acceptance of our sNDA for Camzyos in adolescents with symptomatic oHCM with a PDUFA date of September 30, 2026. Additionally, Sotyktu was approved in the U.S. and EU for the treatment of adults with active PsA and Opdivo was approved in the U.S. and EU for cHL.

We continue to view business development as an important component of our strategy, focusing on opportunities where we can add strategic value and deliver returns. In May 2026, we entered into global strategic collaboration and license agreements with Hengrui to develop and commercialize 13 early stage assets in oncology, hematology and immunology. For additional information relating to this arrangement, refer to "Item 1. Financial Statements — Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements".

We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. As previously announced, our ongoing strategic productivity initiative includes acceleration of the delivery of medicines to patients by evolving and streamlining our enterprise operating model in key areas such as R&D, manufacturing, commercial and other functions. As a result of an expansion in 2025, we expect to realize annual cost savings of approximately $2.0 billion by the end of 2027. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.

Financial Highlights

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Six Months Ended June 30,"],["Dollars in millions, except per share data","2026","","2025","","2026","","2025"],["Total Revenues","$","12,973","","","$","12,269","","","$","24,462","","","$","23,470"],["Diluted earnings/(loss) per share"],["GAAP","$","1.62","","","$","0.64","","","$","2.93","","","$","1.85"],["Non-GAAP","2.04","","","1.46","","","3.62","","","3.26"]]
[[/GREPCENT_TABLE]]

Revenues increased 6% during the second quarter of 2026 and 4% year-to-date, primarily reflecting higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis, which was partially offset by the impact of generics across the remainder of the Legacy Portfolio.

27

The increase in GAAP EPS of $0.98 and $1.08 for the second quarter of 2026 and year-to-date, respectively, was primarily due to a one-time Acquired IPRD charge in 2025 and the impact of certain specified items, including lower amortization of acquired intangible assets, and higher revenues in 2026, partially offset by the expiry of royalty income on diabetes products at the end of 2025. After adjusting for specified items, the increase in non-GAAP EPS of $0.58 and $0.36 for the second quarter of 2026 and year-to-date, respectively, was primarily due to the aforementioned Acquired IPRD charge and higher revenues, partially offset by the expiry of royalty income on diabetes products.

Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For further information and reconciliations relating to our non-GAAP financial measures refer to "—Non-GAAP Financial Measures."

Economic and Market Factors

Governmental Actions

Ongoing regulatory focus on prescription drugs has increased pressures across our portfolio. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which have negatively impacted, and may continue to negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. Under the IRA, the HHS announced the "maximum fair price" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026 and the "maximum fair price" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. Additionally, in January 2026, the HHS selected Orencia as a medicine subject to "negotiation" for government-set prices beginning in 2028. It is possible that more of our products could be selected in future years based upon the selection criteria currently utilized by the HHS or potentially expanded future criteria, or that the "maximum fair price" for our previously selected products could be renegotiated, each of which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.

In December 2025, we announced the U.S. Government Agreement pursuant to which BMS will receive certain U.S. tariff relief until January 2029, including for recently imposed tariffs relating to patented pharmaceuticals and associated pharmaceutical ingredients pursuant to the Presidential Proclamation dated April 2, 2026, and will not be subject to future pricing mandates in the U.S. while the agreement remains in effect. However, such exemptions may be terminated or may not be extended. In addition, we remain subject to any current or future pricing mandates implemented outside of the U.S. It is possible that such regulations may result in a material impact on our business and results of operations.

See risk factors on governmental action items included under “Part I—Item 1A. Risk Factors—Product, Industry and Operational Risks—Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins”, “—We could lose market exclusivity of a product earlier than expected”, “—We could experience difficulties, delays and disruptions in our supply chain as well as in the manufacturing, distribution and sale of our products”, “—Changes to tax regulations could negatively impact our earnings” and "—Adverse changes in U.S. and global economic and political conditions could adversely affect our operations and profitability" in our 2025 Form 10-K.

28

Significant Product and Pipeline Approvals

The following is a summary of the significant approvals received in 2026 as of July 30, 2026:

[[GREPCENT_TABLE]]
[["Product","Date","Approval"]]
[[/GREPCENT_TABLE]]

[[GREPCENT_TABLE]]
[["Opdivo","June 2026","EC approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL."],["Sotyktu","May 2026","EC approval of Sotyktu, alone or in combination with methotrexate, for the treatment of active PsA in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic (DMARD) therapy. Japan's Ministry of Health, Labour and Welfare approval of Sotyktu for the treatment of PsA in patients with an inadequate response to existing therapies."],["Breyanzi","April 2026","Japan's Ministry of Health, Labour and Welfare approval of Breyanzi for the treatment of both relapsed or refractory MCL and relapsed or refractory MZL."],["Opdivo","March 2026","FDA approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. EC approval of Opdivo in combination with brentuximab vedotin, for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy."],["Sotyktu","March 2026","FDA approval of Sotyktu for the treatment of adults with active PsA."]]
[[/GREPCENT_TABLE]]

Refer to "—Product and Pipeline Developments" for a listing of other developments in our marketed products and late-stage pipeline since the start of the second quarter of 2026.

Acquisitions, Divestitures, Licensing and Other Arrangements

Refer to "Item 1. Financial Statements—Note 3. Alliances" and "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for information on significant acquisitions, divestitures, licensing and other arrangements.

29

RESULTS OF OPERATIONS

Regional Revenues

The composition of the changes in revenues was as follows:

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Six Months Ended June 30,"],["Dollars in millions","2026","","2025","","% Change","","Foreign Exchange(b)","","2026","","2025","","% Change","","Foreign Exchange(c)"],["United States","$","8,991","","","$","8,519","","","6","%","","\u2014","%","","$","16,779","","","$","16,392","","","2","%","","\u2014","%"],["International","3,664","","","3,481","","","5","%","","2","%","","7,108","","","6,590","","","8","%","","4","%"],["Other(a)","318","","","270","","","18","%","","(3)","%","","575","","","488","","","18","%","","(5)","%"],["Total revenues","$","12,973","","","$","12,269","","","6","%","","\u2014","%","","$","24,462","","","$","23,470","","","4","%","","1","%"]]
[[/GREPCENT_TABLE]]

(a)    Includes royalties and alliance-relat

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm
Complete FY 2025 MD&A: /company/BMY/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-11
Report date: 2025-12-31

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this 2025 Form 10-K to enhance the understanding of our results of operations, financial condition and cash flows. Certain amounts in this 2025 Form 10-K may not sum due to rounding. Percentages have been calculated using unrounded amounts.

The comparison of 2024 to 2023 results has been omitted from this Form 10-K and is incorporated by reference from our Form 10-K for the year ended December 31, 2024 “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed on February 12, 2025.

EXECUTIVE SUMMARY

Bristol-Myers Squibb Company is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Refer to the Summary of Abbreviated Terms at the end of this 2025 Form 10-K for definitions of capitalized terms used throughout the document.

In 2025, we have achieved multiple regulatory approvals across our portfolio, including the: (i) approval of Breyanzi for adults with relapsed or refractory FL and MCL in the EU, (ii) approval of Camzyos for the treatment of symptomatic obstructive HCM in Japan, (iii) approval of Opdivo + Yervoy as a first-line treatment of adult patients with unresectable or advanced HCC in both the U.S. and the EU, (iv) approval of Opdivo + Yervoy for first-line treatment of adults and pediatric patients 12 years and older with unresectable or metastatic MSI-High or dMMR colorectal cancer in the U.S. and Japan, (v) approval of Opdivo as a perioperative regimen for resectable high risk NSCLC in the EU, (vi) approval of Opdivo Qvantig for use across multiple adult solid tumors in the EU, and (vii) approval of Breyanzi for the treatment of adults with relapsed or refractory MZL in the U.S. Additionally, we received label updates from the FDA that have reduced or removed certain patient monitoring requirements associated with the use of Camzyos, Breyanzi and Abecma.

We continue to pursue activities to advance and expand our pipeline through our internal research and development efforts as well as through business development activities. In 2025, the Company (i) acquired Orbital Therapeutics, which provided the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease, (ii) entered into a strategic collaboration with BioNTech to co-develop and co-commercialize BioNTech's investigational bispecific antibody pumitamig (BNT327/BMS986545) across multiple solid tumor types, (iii) acquired a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, and (iv) expanded our development and manufacturing capabilities by opening a new radiopharmaceutical facility in Indianapolis, Indiana, which will support RPTs acquired in connection with the RayzeBio acquisition. For additional information relating to our acquisitions, divestitures, licensing and other arrangements refer to "Item 8. Financial Statements and Supplementary Data — Note 3. Alliances" and "Item 8. Financial Statements and Supplementary Data— Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements".

We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. As previously announced, our ongoing strategic productivity initiative includes acceleration of the delivery of medicines to patients by evolving and streamlining our enterprise operating model in key areas such as R&D, manufacturing, commercial and other functions. We continue to expect to realize approximately $2.0 billion in cost savings by the end of 2027 in connection with the 2025 expansion of our ongoing strategic productivity initiative. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.

41

Financial Highlights

[[GREPCENT_TABLE]]
[["","Year Ended December 31,"],["Dollars in millions, except per share data","2025","","2024"],["Total Revenues","$","48,194","","","$","48,300"],["Diluted Earnings/(Loss) Per Share"],["GAAP","$","3.46","","","$","(4.41)"],["Non-GAAP","6.15","","","1.15"]]
[[/GREPCENT_TABLE]]

Revenues were relatively flat in 2025. Demand increased across the Growth Portfolio and for Eliquis, which was offset by the impact of generics across the remainder of the Legacy Portfolio. Additionally, revenues were impacted by higher U.S. government channel rebates in 2025. We expect continued generic erosion within our Legacy Portfolio in 2026 primarily due to Revlimid and Pomalyst in the U.S.

The $7.87 change in GAAP EPS in 2025 was primarily due to lower Acquired IPRD charges, the impact of certain specified items, including lower amortization of acquired intangible assets and lower intangible asset impairment charges, and cost savings from our ongoing strategic productivity initiative in 2025. After adjusting for specified items, the $5.00 increase in non-GAAP EPS was primarily due to the aforementioned lower Acquired IPRD charges and cost savings from our ongoing strategic productivity initiative.

Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For a detailed listing of all specified items and further information, reconciliations and changes to our non-GAAP financial measures refer to “—Non-GAAP Financial Measures.”

Economic and Market Factors

Governmental Actions

As regulators continue to focus on prescription drugs, our products are facing increased pressures across the portfolio. These pressures stem from legislative and policy changes, including price controls, pharmaceutical market access, discounting, changes to tax and importation laws and other restrictions in the U.S., EU and other regions around the world. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which have negatively impacted, and may continue to negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. In August 2024, as part of the first round of government price setting pursuant to the IRA, the HHS announced the "maximum fair price" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026. In November 2025, the HHS announced the "maximum fair price" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. In January 2026, the HHS selected Orencia as a medicine subject to "negotiation" for government-set prices beginning in 2028. It is possible that more of our products could be selected in future years based upon the selection criteria currently utilized by the HHS or potentially expanded future criteria, or that the "maximum fair price" for our previously selected products could be renegotiated, each of which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.

In December 2025, we announced the U.S. Government Agreement pursuant to which we agreed to, among other things: (i) provide Eliquis for free to the Medicaid program effective January 1, 2026; (ii) donate more than seven tons of Eliquis API to fill the U.S. Strategic Active Ingredient Reserve; (iii) enable direct-to-patient access to Sotyktu, Zeposia, Reyataz, Baraclude and Orencia for cash-paying patients at discounts approximately 80% off current list prices; (iv) adopt a more balanced pricing approach for new launches across developed nations; and (v) continue to expand domestic production. This agreement, and any potential future agreements with government entities, by us or our competitors, could result in reduced prices and reimbursement for certain of our or competing products and may impact our cash flows and results of operations.

Further, the U.S. and other countries have recently imposed, and may continue to impose, new tariffs. While pharmaceuticals are largely exempt from the tariffs imposed in 2025, such exemptions may be terminated or may not apply to any future tariffs. In accordance with the U.S. Government Agreement, BMS will receive certain U.S. tariff relief until January 2029 and will not be subject to future pricing mandates in the U.S., however, such exemptions may be terminated or may not be extended. In addition, we remain subject to any current or future pricing mandates implemented outside of the U.S. It is possible that such regulations may result in a material impact on our business and results of operations.

42

At the state level, multiple states have passed, are pursuing or are considering government action via legislation or regulations to change drug pricing and reimbursement (e.g., establishing prescription drug affordability boards, implementing manufacturer mandates tied to the Federal Public Health Service Act drug pricing program, etc.). Some of these state-level actions may also influence federal and other state policies and legislation. Given the current uncertainty surrounding the adoption, timing and implementation of many of these measures, as well as pending litigation challenging such laws, we are unable to predict their full impact on our business. However, such measures could modify or decrease access, coverage, or reimbursement of our products, or result in significant changes to our sales or pricing practices, which could have a material impact on our revenues and results of operations. With respect to the Federal Public Health Service Act drug pricing program, certain states have enacted laws regulating manufacturer pricing obligations under the program to date. Several additional states are considering similar potential legislation or other government actions, and we expect other states may do the same in the future.

See risk factors on these items included under “Part I—Item 1A. Risk Factors—Product, Industry and Operational Risks—Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins”, “—We could lose market exclusivity of a product earlier than expected”, “—We could experience difficulties, delays and disruptions in our supply chain as well as in the manufacturing, distribution and sale of our products” and “—Changes to tax regulations could negatively impact our earnings”.

43

Significant Product and Pipeline Approvals

The following is a summary of the significant approvals received:

[[GREPCENT_TABLE]]
[["Product","Date","Approval"]]
[[/GREPCENT_TABLE]]

[[GREPCENT_TABLE]]
[["Breyanzi","December 2025","FDA approval of Breyanzi for the treatment of adult patients with relapsed or refractory MZL who have received at least two prior lines of systemic therapy."]]
[[/GREPCENT_TABLE]]

[[GREPCENT_TABLE]]
[["Breyanzi","November 2025","EC approval of Breyanzi for the treatment of adult patients with relapsed or refractory MCL after at least two lines of systemic therapy including a Bruton's tyrosine kinase inhibitor."]]
[[/GREPCENT_TABLE]]

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/BMY/mda/fy2025/
All MD&A years: /company/BMY/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/BMY/mda/fy2024/): filed 2025-02-12; accession 0000014272-25-000039 (https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)
- [FY 2023 MD&A](/company/BMY/mda/fy2023/): filed 2024-02-13; accession 0000014272-24-000044 (https://www.sec.gov/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm)
- [FY 2022 MD&A](/company/BMY/mda/fy2022/): filed 2023-02-14; accession 0000014272-23-000046 (https://www.sec.gov/Archives/edgar/data/14272/000001427223000046/bmy-20221231.htm)
- [FY 2021 MD&A](/company/BMY/mda/fy2021/): filed 2022-02-09; accession 0000014272-22-000051 (https://www.sec.gov/Archives/edgar/data/14272/000001427222000051/bmy-20211231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

| FDA-listed trade name | Active ingredient | Application | Original approval |
| --- | --- | --- | --- |
| OPDIVO QVANTIG | NIVOLUMAB;HYALURONIDASE-NVHY | [BLA761429](/drug/bla-761429/) | 2024-12-27 |
| OPDIVO QVANTIG | NIVOLUMAB;HYALURONIDASE-NVHY | [BLA761381](/drug/bla-761381/) | 2024-12-27 |
| OPDUALAG | NIVOLUMAB;RELATLIMAB-RMBW | [BLA761234](/drug/bla-761234/) | 2022-03-18 |
| IDHIFA | ENASIDENIB MESYLATE | [NDA209606](/drug/nda-209606/) | 2017-08-01 |
| EMPLICITI | ELOTUZUMAB | [BLA761035](/drug/bla-761035/) | 2015-11-30 |
| DAKLINZA | DACLATASVIR DIHYDROCHLORIDE | [NDA206843](/drug/nda-206843/) | 2015-07-24 |
| OPDIVO | NIVOLUMAB | [BLA125527](/drug/bla-125527/) | 2015-03-04 |
| OPDIVO | NIVOLUMAB | [BLA125554](/drug/bla-125554/) | 2014-12-22 |
| REYATAZ | ATAZANAVIR SULFATE | [NDA206352](/drug/nda-206352/) | 2014-06-02 |
| ELIQUIS | APIXABAN | [NDA202155](/drug/nda-202155/) | 2012-12-28 |
| NULOJIX | BELATACEPT | [BLA125288](/drug/bla-125288/) | 2011-06-15 |
| YERVOY | IPILIMUMAB | [BLA125377](/drug/bla-125377/) | 2011-03-25 |
| SPRYCEL | DASATINIB | [NDA022072](/drug/nda-022072/) | 2006-06-28 |
| SPRYCEL | DASATINIB | [NDA021986](/drug/nda-021986/) | 2006-06-28 |
| REVLIMID | LENALIDOMIDE | [NDA021880](/drug/nda-021880/) | 2005-12-27 |

All 62 approved applications for BMY: /drug/#BMY

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/BMY.md · JSON record: /company/BMY.json · verified financials: /company/BMY/financials.json / /company/BMY/financials.csv · machine TOC for the whole site: /llms.txt